Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0299 • ACR Convergence 2022
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
Yoshiya Tanaka¹, Tatsuya Atsumi², Daniel Aletaha³, Robert Landewé⁴, Beatrix Bartok⁵, Alena Pechonkina⁶, Ling Han⁶, Kahaku Emoto⁷, Shungo Kano⁷, Vijay Rajendran⁸ and Tsutomu Takeuchi⁹, ¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²Hokkaido University, Sapporo, Japan, ³Medical University Vienna, Wien, Austria, ⁴Amsterdam University Medical Center, Meerssen, Netherlands, ⁵Gilead Sciences, Inc., La Jolla, CA, ⁶Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, K.K., Tokyo, Japan, ⁸Galapagos NV, Gent, Belgium, ⁹Keio University and Saitama Medical University, Tokyo, Japan
Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…
Abstract Number: 0398 • ACR Convergence 2022
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
Benjamin Naovarat¹, John Reveille¹, Mark Hwang², Francis Williams³ and Gloria Salazar⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Specialists for Health/Wellmed, Shavano Park, TX, ⁴University of Texas Medical School at Houston/McGovern Medical School, Houston, TX
Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…
Abstract Number: 0558 • ACR Convergence 2022
Molecular Interplay Between Mammalian Target of Rapamycin (mTOR) and the YAP Pathway Mediates Rheumatoid Arthritis Synovial Fibroblast Activation
Brianne Barker¹, Megan Hanlon², Siobhan Wade¹, Douglas Veale³, Ursula Fearon¹ and Mary Canavan⁴, ¹Trinity College Dublin, Dublin, Ireland, ²Molecular Rheumatology, Dublin, Ireland, ³St. Vincent's University Hospital, Blackrock, Dublin, Ireland, ⁴Trinity College, Dublin, Ireland
Background/Purpose: mTOR is a metabolic master regulator of both innate and adaptive immunity, however its exact role in synovial fibroblasts is unknown. RA synovial fibroblasts…
Abstract Number: 0597 • ACR Convergence 2022
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts
Farheen Sultan Shaikh, Anil Singh, Paul Panipinto and Salahuddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: TNF-α is a proinflammatory cytokine in rheumatoid arthritis that exerts effect through specific receptors TNFR1/2. Though it is a primary therapeutic target, there exist…
Abstract Number: 0615 • ACR Convergence 2022
Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis
Qi Cheng, Mo chen, Mengdan Liu, Xin chen, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…
Abstract Number: 0711 • ACR Convergence 2022
Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study
Bolette Soussi¹, Kirsten Duch¹, René Cordtz¹, Christian Bork², Salome Kristensen¹, Erik Schmidt², Jesper Lindhardsen³ and Lene Dreyer¹, ¹Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, ³Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Results from previous studies investigating mortality trends in patients with rheumatoid arthritis (RA) have been inconsistent, most likely due to varying cohort sizes and…
Abstract Number: 0774 • ACR Convergence 2022
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Marthe K. Brun¹, Kristin Hammersbøen Bjørlykke², Marte Kathrine Viken³, Grete-Elisabeth Stenvik¹, Rolf Klaasen³, Johanna Elin Gehin³, David Warren³, Joe Sexton¹, Espen Haavardsholm¹, Jørgen Jahnsen², Benedicte Alexandra Lie³, Nils Bolstad³, Kristin Kaasen Jørgensen², Guro Løvik Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Immunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been…
Abstract Number: 0887 • ACR Convergence 2022
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Byung Wook Song, Dong-Hyuk Moon, Aran Kim and Seung-Geun Lee, Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…
Abstract Number: 0903 • ACR Convergence 2022
Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis
Emil Rydell¹, Lennart Jacobsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…
Abstract Number: 0919 • ACR Convergence 2022
Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
Siddharth Jain¹, Varun Dhir², Amita Aggarwal³, Ranjan Gupta⁴, Bidya Laishangtham¹, Aastha Khullar¹, Shankar Naidu¹, Veena Dhawan¹, Shefali Sharma⁵, Aman Sharma⁶ and sanjay jain¹, ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴All India Institute of Medical Sciences, New Delhi, India, ⁵PGIMER< Chandigarh, Chandigarh, India, ⁶PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: Methotrexate (MTX) is the gold standard, first-line therapy for rheumatoid arthritis (RA). However, not all patients respond to MTX, and the predictors of its…
Abstract Number: 0936 • ACR Convergence 2022
Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial
Jin Kyun Park¹, Yun Jong Lee², Kichul Shin³, Eun Ha Kang², You-Jung Ha², Min Jung Kim⁴, Jun Won Park⁵, SE RIM CHOI⁵, Mi Hyeon Kim⁵, Ji In Jung⁵, Ju Yeon Kim⁵, Kevin Winthrop⁶ and Eun Bong Lee⁵, ¹Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Oregon Health & Science University, Portland, OR
Background/Purpose: Methotrexate (MTX) significantly decreases the vaccine response to pneumococcal and seasonal influenza vaccines and temporarily discontinuing MTX for 2 weeks in patients with rheumatoid…
Abstract Number: 1146 • ACR Convergence 2022
Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis
Chuan Fu Yap¹, Paul Martin², Darren Plant¹, John Bowes¹, Kazuyoshi Ishigaki³, Saori Sakaue⁴, Alex Macgregor⁵, Suzanne Verstappen¹, Anne Barton¹, Soumya Raychaudhuri⁶ and Sebastien Viatte¹, ¹The University of Manchester, Manchester, United Kingdom, ²The University of Manchester, Oberhaching, Germany, ³Riken, Bunkyo-ku, Tokyo, Japan, ⁴Broad Institute of Harvard and MIT, Cambridge, MA, ⁵The University of East Anglia, Norwich, United Kingdom, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) genetic susceptibility has been well studied with five amino acid positions within the HLA explaining most of the association. Although genome…
Abstract Number: 1261 • ACR Convergence 2022
Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
Peter Mandl¹, Irina Gessl¹, Georgios Filippou², Silvia Sirotti³, Lene Terslev⁴, Carlos Pineda⁵, Helen Keen⁶, Marina Backhaus⁷, David Bong⁸, Edoardo Cipolletta⁹, Paz Collado¹⁰, Christian Dejaco¹¹, Andrea Delle Sedie¹², Christina Duftner¹³, Hilde Berner Hammer¹⁴, Annmaria Iagnocco¹⁵, Zunaid Karim¹⁶, Esperanza Naredo¹⁷, Wolfgang Schmidt¹⁸, Marcin Szkudlarek¹⁹, Giorgio Tamborrini²⁰, Priscilla Wong²¹, Emilio Filippucci⁹, Peter Balint²² and Maria-Antonietta D'Agostino²³, ¹Medical University of Vienna, Vienna, Austria, ²Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, ³Università degli Studi di Milano, Milano, Italy, ⁴Copenhagen University Hospital Glostrup, Glostrup, Denmark, ⁵Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ⁶University of Western Australia, Perth, Australia, ⁷Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, ⁸Instituto Poal de Reumatologia, Universitat de Barcelona, Barcelona, Spain, ⁹Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, ¹⁰Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹¹Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ¹²University of Pisa, Pisa, Pisa, Italy, ¹³Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria, ¹⁴Diakonhjemmet hospital, Jar, Norway, ¹⁵Academic Rheumatology Centre, University of Turin, Turin, Italy, ¹⁶Department of Rheumatology, Mid Yorkshire NHS Trust, Yorkshire, United Kingdom, ¹⁷Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ¹⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology, Berlin-Buch, Berlin, Germany, ¹⁹Department of Rheumatology, Copenhagen University Hospital at Køge, Copenhagen, Denmark, ²⁰Ultrasound Center and Institute for Rheumatology, Basel, Switzerland, ²¹Division of Rheumatology, The Chinese University of Hong Kong, Hong-Kong, Hong Kong, ²²3rd. Department of Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ²³Catholic University of Sacred Heart, Roma, Italy
Background/Purpose: Structural damage in rheumatoid arthritis (RA) includes bone erosions, cartilage changes, and joint malalignment; historically evaluated with conventional radiography. Ultrasound (US) has been shown…
Abstract Number: 1387 • ACR Convergence 2022
Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
Ran Jin¹, Megan Hughes², Emily Goddard², James Piercy², Delphine Courmier², Rachael Meadows² and Waldemar Radziszewski¹, ¹Amgen, Inc., Thousand Oaks, CA, ²Adelphi Group, Bollington, United Kingdom
Background/Purpose: ABP 501 is the first adalimumab biosimilar approved by the European Medicines Agency. A clinical trial demonstrated biosimilarity between ABP 501 and the reference…
Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Lucia Cristina Dominguez Casas¹, Mª Paz Rodriguez Cundin², Trinidad Dierssen Sotos³, Nuria Vegas Revenga⁴, Alfonso Corrales⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Universidad de Cantabria, Santander, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].